The blue pill (sildenafil) and its descendants: an overview

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA.1993;270(1):83-90.10.1001/jama.1993.03510010089036Search in Google Scholar

2. Gong B, Ma M, Xie W, Yang X, Huang Y, Sun T et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(10):1731-40. doi: 10.1007/s11255-017-1644-5.Search in Google Scholar

3. Izdebski Z. Seksualność Polakow na początku XXI wieku. Studium badawcze. Krakow: Wyd. UJ; 2012:287-92.Search in Google Scholar

4. Szurgociński A. Zaburzenia erekcji w Polsce. Grodzisk Mazowiecki: Vedi Clinic;2016.Search in Google Scholar

5. Moreland RB, Hsieh G, Nakane M, Brioni JD. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther. 2001;296(2):225-34.Search in Google Scholar

6. Rabijewski M. Zaburzenia erekcji - etiologia i leczenie. Przegl. Urol. 2006;4(38):46.Search in Google Scholar

7. Izdebski Z. Obawy i trudności w życiu seksualnym. Rocz Lubus. 2006;32(2):13-8.Search in Google Scholar

8. Dęmbe K, Jasik M, Stawicki S, Karnafel W. Patogeneza i częstość zaburzeń erekcji u chorych na cukrzycę. Seksuol Pol. 2004;2 (2):51-54.Search in Google Scholar

9. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804-14. doi: 10.1016/j.eururo.2010.02.020.Search in Google Scholar

10. Ferguson JE, Carson CC. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. Arab J Urol. 2013;11(3):222-229. doi: 10.1016/j. aju.2013.07.009.Search in Google Scholar

11. Woroń J, Kostka-Trąbka E. Zaburzenia erekcji jako wynik niepożądanego działania lekow. Seksuol Pol. 2005;3:18-22.Search in Google Scholar

12. Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820-827.Search in Google Scholar

13. Rosen RC. Psychogenic erectile dysfunction. Classification and management. Urol Clin North Am. 2001;28(2):269-78.10.1016/S0094-0143(05)70137-3Search in Google Scholar

14. Reisman Y, Hind A, Varaneckas A, Motil I. Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA)-A Second Generation Technology. Int J Impot Res. 2015;27(3):108-12. doi: 10.1038/ijir.2014.41.Search in Google Scholar

15. Snyder PJ, Ellenberg SS, Farrar JT. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-24. doi: 10.1056/NEJMc 1603665.Search in Google Scholar

16. Anaissie J, Hellstrom WJ. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. Res Rep Urol. 2016;8:123.Search in Google Scholar

17. Altwein JE, Keuler FU. Oral treatment of erectile dysfunction with apomorphine SL. Urol Int. 2001;67(4):257-63.10.1159/00005100111741126Search in Google Scholar

18. Rabijewski M, Papierska L. Pathogenesis and treatment of erectile dysfunction. Ger Pol. 2007;1:203-8.Search in Google Scholar

19. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397-1404.10.1056/NEJM1998051433820019580646Search in Google Scholar

20. McCullough AR. Four-year review of sildenafil citrate. Reviews in Urology. 2002;4,Suppl 3:26.Search in Google Scholar

21. Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman Metal. British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med. 2008;5:1841-65.10.1111/j.1743-6109.2008.00773.x18298470Search in Google Scholar

22. Lew-Starowicz Z. Inhibitory fosfodiesterazy typu 5 - podobieństwa i rożnice. Seksuol Pol. 2003;(2):79-82.Search in Google Scholar

23. Liu Y. The tale of Viagra patents: comparative studies of the global challenges in China and other countries. 2013;18:523-33.Search in Google Scholar

24. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T. 2013;38(7):407-19.Search in Google Scholar

25. Jiann BP. Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. Urol Sci. 2016;27 (2):66-70.10.1016/j.urols.2016.04.003Search in Google Scholar

26. Cho MC, Paick JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014;10:341-54. doi: 10.2147/TCRM.S39727.Search in Google Scholar

27. Zhao C, Kim SW, Yang DJ, Kim JJ, Park NC, Lee SW et al. Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double- Blind, Placebo-Controlled Trial. Eur Urol. 2011;60(2):380-7. doi: 10.1016/j.eururo.2011.03.025.Search in Google Scholar

28. Kim TE, Kim BH, Kim JR, Lim KS, Hong JH, Kim KP et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2009;68(1):43-6. doi: 10.1111/j.1365-2125.2009.03404.x.Search in Google Scholar

29. http://www.mims.com/malaysia/drug/info/zydena/Search in Google Scholar

30. LevitraR (vardenafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London, GB. 2009. Last update: 06/04/2017Search in Google Scholar

31. CialisR (tadalafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London, GB. 2007. Last update: 15/06/2016.Search in Google Scholar

32. ViagraR (sildenafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London, GB. 2008. Last update: 12/07/2016Search in Google Scholar

33. SpedraR (avanafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London, GB. 2013. Last update: 10/03/2015.Search in Google Scholar

34. Stendra (avanafil), prescribing information. Mountainview, Calif.: Vivus, Inc.; April 2012.Search in Google Scholar

35. Staxyn (vardenafil ODT), prescribing information. Wayne, NJ.; Bayer Healthcare/GlaxoSmithKline; revised April 2011.Search in Google Scholar

36. Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000;28(4):392-7.Search in Google Scholar

37. Jetter A, Kinzig‐Schippers M, Walchner‐Bonjean M, Hering U, Bulitta J, Schreiner P et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 2002;71(1):21-9.10.1067/mcp.2002.12123611823754Search in Google Scholar

38. Young JM. Vardenafil. Expert. Opin. Investig. Drugs 2002;11:1487-96.Search in Google Scholar

39. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur. J. Med. Res. 2002;7:435-46.Search in Google Scholar

40. Kloner RA, Mullin SH, Shook T et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J. Urol. 2003;170 (2):S46-50.10.1097/01.ju.0000075055.34506.5912853773Search in Google Scholar

41. Swearingen D, Nehra A, Morelos S, Peterson CA. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context. 2013;26:212248. doi: 10.7573/dic.212248.Search in Google Scholar

42. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P et al. Safety of sildenafi l citrate: review of 67 double-blind placebocontrolled trials and the postmarketing safety database. Int J Clin Pract. 2010;64(2):240-55.10.1111/j.1742-1241.2009.02254.x281044819900167Search in Google Scholar

43. Kuczerowski R. Nowe możliwości leczenia zaburzeń erekcji u mężczyzn z cukrzycą typu 2. Diabetologia Kliniczna 2015;4 (4):158-62. doi: 10.5603/DK.2015.0017.Search in Google Scholar